In the tirzepatide cardiovascular trial, researchers assigned two named drugs. This separate bowel disease study compared prescriptions from medical records, with several GLP-1 drugs grouped into one comparator [1].
What the records showed
Researchers matched 3,042 adults with inflammatory bowel disease in each group. Median follow-up was 540 days. Tirzepatide was associated with a lower hazard of intravenous steroid use (adjusted hazard ratio 0.81, 95% CI 0.68 to 0.94) [1].
The adjusted hazard ratio for the combined IBD outcome was 0.86 (95% CI 0.73 to 0.97). Hospitalization, emergency visits and bowel surgery did not show statistically clear differences.
What the comparison can establish
The records compare prescribing groups. Database matching cannot account for all differences in disease activity or why a clinician chose a drug. The study cannot establish that tirzepatide treats inflammatory bowel disease or that it improves outcomes versus a specific GLP-1 drug.